iBio (IBIO) Research & Development (2010 - 2026)
iBio (IBIO) posted quarterly Research & Development of $3.3 million for Q1 2026, up 70.72% year-over-year from $1.9 million in Q1 2025, and down 23.97% quarter-over-quarter from $4.3 million in Q4 2025.
iBio (IBIO) Research & Development (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Research & Development for 17 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 70.72% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $14.3 million (up 129.74% YoY), while the FY2025 annual figure was $8.3 million, up 60.31% from the prior year.
- Research & Development slipped to $3.3 million in Q1 2026 per IBIO's latest filing, from $4.3 million in the prior quarter.
- Across five years, Research & Development topped out at $4.3 million in Q4 2025 and bottomed at $904000.0 in Q1 2024.
- Historically, Research & Development has averaged $2.5 million across 5 years, with a median of $2.6 million in 2022.
- Annual changes were most pronounced in 2024 — Research & Development sank 71.94% — and 2025, when it jumped 182.81%.
- iBio's Research & Development stood at $2.8 million in 2022, then sank by 44.76% to $1.5 million in 2023, then grew by 22.28% to $1.9 million in 2024, then soared by 128.02% to $4.3 million in 2025, then retreated by 23.97% to $3.3 million in 2026.
- Business Quant data shows IBIO's Research & Development at $3.3 million in Q1 2026, $4.3 million in Q4 2025, and $3.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - | 3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.25 Mn |
| Dec 31, 2025 | 4.28 Mn |
| Sep 30, 2025 | 3.55 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 904,000.00 |
| Dec 31, 2023 | 1.54 Mn |
| Sep 30, 2023 | 1.61 Mn |
| Jun 30, 2023 | 4.06 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 3.27 Mn |
| Dec 31, 2021 | 1.86 Mn |
| Sep 30, 2021 | 1.13 Mn |
| Jun 30, 2021 | 3.10 Mn |
| Mar 31, 2021 | 2.16 Mn |